NASDAQ·Biological Products, (No Diagnostic Substances)
RXRX
RECURSION PHARMACEUTICALS, INC.
RECURSION PHARMACEUTICALS, INC. (ticker: RXRX) is an NASDAQ-listed biological products, (no diagnostic substances) company. DredgeCap's structured extraction of RXRX's SEC filings surfaces 1 active risk signal, including 1 auditor-change signal. RXRX reported $6.47M in revenue and -$117.50M for the period ending 2026-03-31, with operating cash flow of -$81.10M. Cash and equivalents stood at $654.47M (up 30.8% year-over-year). Total assets of $1.34B exceed total liabilities of $314.75M. Each signal on this page is sourced verbatim from the underlying SEC filing. Use the tabs above to drill into auditor history, going-concern citations, dilution mechanics, cash runway, and the full risk-flag inventory.
RXRX SEC Filings
Full cached SEC EDGAR filing history for RXRX, grouped by form type and sorted newest-first within each group. 0 filings across 0 form types.
Filings sourced verbatim from SEC EDGAR submissions metadata. “Structured” links route to DredgeCap's per-filing renderer (XBRL-backed financials + cited highlights) when available; the EDGAR link always points to the canonical accession index on sec.gov.